News - North America, Dermatologicals

Filter

Popular Filters

1 to 25 of 27 results

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma

18-03-2014

Pierre Fabre Dermatologie has obtained marketing authorization from the US Food and Drug Administration…

DermatologicalsHemangeolNorth AmericaPharmaceuticalPierre FabreRegulationUSA

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

11-03-2014

US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

Everett Labs acquires Quinnova Pharma to diversify US market presence

27-12-2013

US specialty pharma firm Everett Laboratories, a subsidiary of Spain’s Exeltis, has acquired Quinnova…

Amneal EnterprisesDermatologicalsEverett LaboratoriesExeltisMergers & AcquisitionsNorth AmericaPharmaceuticalQuinnova PharmaceuticalsUSAWomen's Health

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

ICAAC: Positive preliminary results of new luliconazole formulation in onychymycosis trial

16-09-2013

Luliconazole, a medication approved in Japan for the treatment of superficial mycosis in a 1% formulation,…

DermatologicalsLuliconazoleNihon NohyakuNorth AmericaPharmaceuticalResearch

Galderma drug is first FDA-approved facial erythema of rosacea treatment

27-08-2013

Switzerland-headquartered Galderma Laboratories says that the US Food and Drug Administration has approved…

brimonidineDermatologicalsGaldermaMirvasoNorth AmericaPharmaceuticalRegulation

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

Galen in upfront $4.5million deal with Novo Research for US rights for Synera pain relief patch

11-07-2013

Canada's Nuvo Research (TSX: NRI) today (July 11) announced that its wholly owned subsidiary, ZARS Pharma,…

DermatologicalsGalen USLicensingNorth AmericaNuvo ResearchPharmaceuticalSyneraZARS Pharma

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

News briefs: Dr Reddy's launches generic Accutane; Cyprus drug shortages

29-03-2013

Indian drugmaker Dr Reddy's Laboratories (NYSE: RDY) says it launched Zenatane (isotretinoin capsules…

AccutaneDermatologicalsDr Reddy's LaboratoriesEuropeGenericsHealthcareMarkets & MarketingNorth AmericaPharmaceuticalZenatane

Briefs: Glenmark challenges Bayer patent; FDA delays Merck & Co's sugammadex

18-03-2013

Indian drugmaker Glenmark Generics confirms that it seeking US Food and Drug Administration approval…

BayerBridionDermatologicalsFinacea GelGenericsGlenmark PharmaceuticalsMerck & CoNeurologicalNorth AmericaPatentsPharmaceuticalRegulationsugammadex

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study

10-02-2013

Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Shire's Dermagraft cleared in Canada; settles Intuniv litigation

06-09-2012

Ireland headquartered Shire (LSE: SHP), NASDAQ: SHPG) says that its lead regenerative medicine product,…

Anchen PharmaceuticalsDermagraftDermatologicalsDiabetesGenericsIntunivNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireTWi Pharmaceuticals

Watson confirms patent challenges for Xopenox HFA and Epiduo Gel

31-07-2012

US generics drugmaker Watson Pharmaceuticals NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories…

Dainippon Sumitomo PharmaDermatologicalsEpiduo GelGaldermaGenericsLegalNorth AmericaRegulationRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenox

US FTC puts conditions on Novartis buy of Fougera

17-07-2012

The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalTolmar

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Ranbaxy gains US FDA approval for Absorica

29-05-2012

India's largest drugmaker Ranbaxy Laboratories (AB: BO) has received approval from the US Food and Drug…

AbsoricaCipher PharmaceuticalsDermatologicalsIsotretinoinNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

LEO Pharma gets FDA nod for Picato

29-01-2012

Independent Danish drugmaker LEO Pharma says that the US Food and Drug Administration has approved its…

DermatologicalsLEO PharmaNorth AmericaPharmaceuticalPicatoRegulation

Stellar Pharma to sell Apricus MycoVa in Canada

04-01-2012

USA-based Apricus Biosciences (Nasdaq: ARI) has signed an exclusive license agreement with Canada’s…

Apricus BioscienceDermatologicalsLicensingMycoVaNorth AmericaPharmaceuticalStellar Pharmaceuticals

1 to 25 of 27 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top